QUICK ANSWER · AEO / GEO
An identity-sensitive supplier and compounding term that must be separated from albumin-binding CJC-1295 DAC; FDA found no nonclinical or clinical data adequate to assess CJC-1295 free base or acetate.
ENTITY FACTS
What should readers identify first?
What remains unknown?
English translation is not yet verified for 5 excerpt(s). This is a language gap, not an absence of risks or uncertainty.
Read original excerpts (Thai / mixed language)
- ลำดับ peptide และรูปแบบเคมีที่ exact product ใช้เมื่อเขียนเพียง CJC-1295 without DAC
- เภสัชจลนศาสตร์ ความแรง และกิจกรรมทางชีวภาพของ free base หรือ acetate ในมนุษย์
- ประสิทธิผลต่อผลลัพธ์ทางคลินิกใด ๆ
- ความปลอดภัยระยะยาว ภูมิคุ้มกันต่อ peptide และผลจากสิ่งเจือปน
- สถานะผลิตภัณฑ์ระดับประเทศเมื่อไม่มีเลขทะเบียนหรือเอกสารอนุมัติที่ตรวจสอบได้
What limits these conclusions?
English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.
Read original excerpts (Thai / mixed language)
- FDA review พบการตั้งชื่อไม่สม่ำเสมอและข้อมูล characterization ที่สำคัญขาดหายไป งานมนุษย์ที่ตีพิมพ์ศึกษา CJC-1295 DAC ในอาสาสมัครสุขภาพดีและวัด PK/PD ไม่ใช่ free base/acetate และไม่ใช่ผลลัพธ์ทางคลินิก การไม่พบเอกสารอนุมัติในการตรวจครั้งนี้ไม่ใช่หลักฐานเด็ดขาดว่าไม่มีการอนุมัติในทุกประเทศ
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://www.fda.gov/media/183891/download
- https://www.fda.gov/media/183819/download
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-meeting-time-and-public-participation-information-december-4-2024-meeting-pharmacy
- https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- https://pubmed.ncbi.nlm.nih.gov/16352683/
- https://pubmed.ncbi.nlm.nih.gov/17018654/
- https://clinicaltrials.gov/study/NCT00267527
- https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
- https://www.ema.europa.eu/en/medicines/download-medicine-data
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is CJC-1295 without DAC?
CJC-1295 without DAC is described pharmacologically as Non-DAC GHRH analogue term / identity-sensitive research peptide. An identity-sensitive supplier and compounding term that must be separated from albumin-binding CJC-1295 DAC; FDA found no nonclinical or clinical data adequate to assess CJC-1295 free base or acetate.
Does CJC-1295 without DAC have strong evidence?
PrimeCoreBio records Evidence Grade U. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is CJC-1295 without DAC approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.